These factors, which are involved in tumor growth and survival, are targeted by anti-angiogenesis treatments, mainly TKI therapies, including the anti-VEGF, anti-mTOR, and the recently introduced anti-MET [also tyrosine-protein kinase Met or hepatocyte growth factor receptor (HGFR)], anti-RET, anti-platelet derived growth factor receptor (PDGFR), and anti-fibroblast growth factor receptors (FGFRs); these therapies have become a weapon of fundamental importance [17]. Here, MET is linked to neoplasm.